Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurological disorders
Marketing
Neurocrine joins in on Tardive Dyskinesia Awareness Week
Neurocrine, maker of the first drug approved by the FDA to treat TD, is throwing its weight behind efforts to improve awareness of the disorder.
Andrea Park
May 6, 2024 10:52am
AZ's Alexion debuts short film highlighting NMOSD community
Apr 18, 2024 2:16pm
FDA expands AZ's Ultomiris to NMOSD after prior rejection
Mar 25, 2024 10:31am
FDA awards Biogen's ALS drug Qalsody an accelerated approval
Apr 25, 2023 2:28pm
Setback at Lundbeck: CGRP migraine drug Vyepti hits trial snag
Aug 18, 2022 12:01pm
Sanofi-Innovent, Astellas, AbbVie-Sosei—Fierce Pharma Asia
Aug 5, 2022 10:39am